TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
DHR

Danaher Corporation

Healthcare · Diagnostics & Research

212.50$ +2.0% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios DHR
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
15.9 17.0 18.9 23.3 24.5 38.6 38.8 33.4 24.1 36.2 43.4 45.0
2.1 3.1 2.9 3.2 3.8 5.5 6.4 7.3 6.5 7.2 7.1 6.6
1.8 1.9 2.1 2.2 2.3 3.3 3.6 4.8 3.5 3.2 3.4 3.1
2.1 3.9 3.5 3.7 4.3 5.6 7.0 8.0 7.0 7.7 7.7 7.2
9.2 18.4 15.2 15.7 17.3 21.9 24.0 23.5 19.7 35.5 25.2 25.4
12.5 13.5 16.5 20.0 18.9 29.8 26.1 30.4 23.5 29.7 32.0 30.9
8.0% 7.4% 6.1% 5.0% 5.3% 3.4% 3.8% 3.3% 4.2% 3.4% 3.1% 3.2%
Margins
52.7% 54.8% 55.6% 55.8% 55.8% 55.7% 56.0% 61.0% 60.8% 58.7% 59.5% 60.9%
18.1% 16.8% 17.7% 17.2% 18.0% 18.8% 19.4% 27.3% 28.3% 21.8% 21.7% 20.9%
13.0% 18.0% 15.1% 13.6% 15.5% 14.3% 16.4% 21.8% 27.1% 19.9% 16.3% 14.7%
16.5% 22.8% 17.4% 15.9% 20.2% 18.5% 24.3% 24.0% 27.7% 24.2% 22.2% 21.4%
Returns
11.1% 11.0% 11.1% 9.5% 9.4% 8.4% 9.2% 14.2% 14.4% 8.9% 7.9% 6.9%
7.0% 5.4% 5.6% 5.3% 5.5% 4.1% 4.8% 7.7% 8.5% 5.6% 5.0% 4.3%
Balance Sheet & Debt
468 12,080 11,305 9,892 8,953 1,975 15,358 19,797 13,849 12,718 14,100 13,803
0.1 3.9 2.9 2.3 2.1 0.4 2.3 2.0 1.5 2.4 1.9 2.0
63.2% 49.1% 50.8% 56.5% 59.0% 48.8% 52.2% 54.3% 59.4% 63.3% 63.9% 62.9%
0.1 0.5 0.5 0.4 0.3 0.7 0.5 0.5 0.4 0.3 0.3 0.4
Per Share
3.63 3.67 3.65 3.53 3.73 3.52 5.07 8.73 9.78 6.38 5.29 5.08
27.81 20.37 24.12 25.96 24.01 24.69 31.01 39.97 36.15 32.15 32.39 34.55
32.65 33.44 32.87 37.33 39.73 41.72 55.33 61.30 67.94 71.98 67.20 73.89
4.60 4.64 4.19 4.12 4.84 4.57 7.54 9.59 9.99 7.78 7.18 7.40

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?